No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
PTGX Protagonist Therapeutics
- 41.490
- +1.950+4.93%
Close Dec 20 16:00 ET
- 41.490
- 0.0000.00%
Post 18:05 ET
2.47BMarket Cap15.14P/E (TTM)
41.680High38.910Low2.37MVolume39.010Open39.540Pre Close97.83MTurnover4.97%Turnover RatioLossP/E (Static)59.60MShares48.89052wk High4.65P/B1.98BFloat Cap21.43052wk Low--Dividend TTM47.67MShs Float50.540Historical High--Div YieldTTM7.01%Amplitude4.470Historical Low41.305Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
Clear Street Launches Healthcare & Biotechnology Equity Research
BTIG Upgrades Protagonist Therapeutics(PTGX.US) to Buy Rating, Maintains Target Price $67
JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $58
Optimistic Buy Rating for Protagonist Therapeutics Driven by Promising Rusfertide Data and Strategic Takeda Partnership
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $50
Heat List
US
Overall
Symbol
Price
% Chg
No Data